Edgar Filing: Templeman Blaine - Form 4

Templeman Form 4										
February 21	, 2019									
FORM		CT A TEC	SECU	DITIES		CHANCE	COMMISSIO		PPROVAL	
	UNITED	SIAIES		shington			N OMB Number:	3235-0287 January 31,		
Check the if no lon subject to Section Form 4	nger STATEN 16.	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES								
Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> Templeman Blaine			Symbol	er Name an O BIOTE		Trading	5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First) (Middle)					(Check all applicable)			
C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE			(Month/Day/Year) 02/19/2019				Director 10% Owner X Officer (give title Other (specify below) See Remarks			
				endment, D onth/Day/Yea	-	1	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
DEKKELE	1, CA 94710						Person			
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deemed Execution D any (Month/Day)		Date, if TransactionAcquired (A) or Code Disposed of (D) y/Year) (Instr. 8) (Instr. 3, 4 and 5) (A)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code V	Amount	(D) Price	(msu: 5 and 4)			
Reminder: Re	port on a separate line	e for each cla	ass of sec	urities bene	-	-	-			
					inforn requir	nation cont ed to respo	spond to the colle ained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

number.

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: Templeman Blaine - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	8)	Acquired (A Disposed of (Instr. 3, 4, 5)	f (D)				
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 3.88	02/19/2019		А		400,000		(1)	02/18/2029	Common Stock	400,000

Reporting Owners

Reporting Owner Name / Address	Relationships								
	Director	10% Owner	Officer	Other					
Templeman Blaine C/O ADURO BIOTECH, INC. 740 HEINZ AVENUE BERKELEY, CA 94710			See Remarks						
Signatures									
/s/ Jennifer Lew, Attorney-in-Fa Templeman	ct for Bla	ine	02/21/20)19					

<u>**Signature of Reporting Person</u>

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Date

(1) The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of February 19, 2019.

Remarks:

Chief Administrative Officer and Chief Legal Officer

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.